Li Xiaoqing, Yang Jing, Chen Xiangjun, Liu Jun, Li Hongrui, Zheng Jine, He Yanli, Chen Zhong, Huang Shiang
Center for Stem Cell Research and Application, Union Hospital of Huazhong University of Science and Technology, Jie Fang Avenue #1277, Wuhan 430022, China.
Cancer Genet Cytogenet. 2007 Jul 15;176(2):166-8. doi: 10.1016/j.cancergencyto.2007.04.013.
The development of imatinib is a milestone in the treatment of chronic myeloid leukemia (CML), and its therapeutic effect has been extensively investigated in CML patients carrying M-bcr and m-bcr BCR/ABL fusion transcripts. However, our knowledge about its therapeutic effect on CML patients with rare BCR/ABL fusion transcripts e19a2(u-bcr) remains sparse. Here, we report on two CML patients with e19a2 transcripts who rapidly progressed into the accelerated phase, further confirming the possibility that 19a2 might be associated with an unfavorable prognosis in CML. Moreover, these patients showed early response to imatinib treatment. Our study highlights the clinical potential of imatinib for this patient subgroup.
伊马替尼的研发是慢性髓性白血病（CML）治疗的一个里程碑，其治疗效果已在携带M-bcr和m-bcr BCR/ABL融合转录本的CML患者中得到广泛研究。然而，我们对其对具有罕见BCR/ABL融合转录本e19a2（u-bcr）的CML患者的治疗效果了解仍然很少。在此，我们报告了两名具有e19a2转录本的CML患者，他们迅速进展为加速期，进一步证实了19a2可能与CML不良预后相关的可能性。此外，这些患者对伊马替尼治疗表现出早期反应。我们的研究突出了伊马替尼对该患者亚组的临床潜力。
